Royalty Pharma PLC

$42.31 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Royalty Pharma PLC

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Stock Analysis

last close $41.94
1-mo return -6.5%
3-mo return -18.2%
avg daily vol. 4.34M
52-week high 56.5
52-week low 34.8
market cap. $16.7B
forward pe 15.6
annual div. 0.68
roe 9.1%
ltg forecast -
dividend yield 1.62%
annual rev. $2.1B
inst own. 60.8%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist